Uranium Chelation by Pyrazine-2-amidoxime: Speciation, Decorporation, and Computational Studies
Inorganic Chemistry · 2026
DOI: 10.1021/acs.inorgchem.5c04432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inorganic Chemistry, 2026. Verfasst von Ashutosh Srivastava und 7 weiteren Autor:innen. Beteiligte Einrichtung: Radiochemistry Division, Bhabha Atomic Research Centre, Mumbai 400085, India. Hauptthemen laut MEDLINE: Uranium, Chelating Agents, Oximes, Density Functional Theory. Die Arbeit nennt 98 Literaturangaben.
Abstract (Originalsprache)
Uranium, being chemo-radiotoxic, requires confinement within a safe environment to prevent severe health consequences. Chelation therapy, utilizing multidentate ligands, is a widely accepted approach for developing effective uranium decorporation treatments. In this study, a systematic investigation of uranium complexation by pyrazine-2-amidoxime (PAM) was undertaken for the first time, employing chemical speciation, in vitro studies, and computational calculations. Potentiometric and spectrophotometric titrations, corroborated by electrospray ionization mass spectrometry (ESI-MS), revealed that PAM forms 1:1 (ML) and 1:2 (ML2) complexes with the uranyl ion (UO22+). PAM acts as a bidentate chelator, coordinating via the oxygen and nitrogen atoms of amidoxime, with high stability constants (log β) of 8.54 ± 0.04 for ML and 16.33 ± 0.07 for ML2 complexes. Density functional theory (DFT) calculations further elucidated the preferred coordination mode, donor-site contributions, and electronic factors governing the stability of the PAM-uranyl complexes. Ex vivo experiments with human erythrocytes (RBCs) confirmed that PAM is cytocompatible and significantly enhanced uranium decorporation from human RBCs, facilitating removal of 25-40% of uranium at 100-200 μM compared to uranium-treated controls. Additionally, PAM effectively reduced uranium content by 10-20% from physiologically relevant proteins such as human serum albumin and from native human blood plasma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Radiochemistry Division, Bhabha Atomic Research Centre, Mumbai 400085, India.
- Radiation Biology & Health Sciences Division, Bhabha Atomic Research Centre, Mumbai 400085, India.
- Analytical Chemistry Division, Bhabha Atomic Research Centre, Mumbai 400085, India.
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India.
- Fuel Chemistry Division, Bhabha Atomic Research Centre, Mumbai 400085, India.
- Radioanalytical Chemistry Division, Bhabha Atomic Research Centre, Mumbai 400085, India.
ORCID-Profile: Naman K Bharti, Pranaw Kumar, Rama Mohana Rao Dumpala, Biswajit Sadhu
Zitieren
APA
Srivastava, A., Ali, M., Bharti, N. K., Sharma, S., Kumar, P., Dumpala, R. M. R., Sadhu, B., & Kumar, A. (2026). Uranium Chelation by Pyrazine-2-amidoxime: Speciation, Decorporation, and Computational Studies. Inorganic Chemistry. https://doi.org/10.1021/acs.inorgchem.5c04432
Vancouver
Srivastava A, Ali M, Bharti NK, Sharma S, Kumar P, Dumpala RMR, et al. Uranium Chelation by Pyrazine-2-amidoxime: Speciation, Decorporation, and Computational Studies. Inorganic Chemistry. 2026. doi:10.1021/acs.inorgchem.5c04432
BibTeX
@article{Srivastava2026,
author = {Srivastava, Ashutosh and Ali, Manjoor and Bharti, Naman K and Sharma, Shikha and Kumar, Pranaw and Dumpala, Rama Mohana Rao and Sadhu, Biswajit and Kumar, Amit},
title = {Uranium Chelation by Pyrazine-2-amidoxime: Speciation, Decorporation, and Computational Studies},
journal = {Inorganic Chemistry},
year = {2026},
doi = {10.1021/acs.inorgchem.5c04432}
}
EUVIMED